Oral Nadolol for the Treatment of Adults With Mild Asthma

Invion

Status and phase: Completed; Phase 2; Phase 1

Conditions: Asthma

Treatments: Drug: nadolol

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00670267

SAND1002

Details and patient eligibility

About

The purpose of this study is to confirm previous observations in asthmatics that chronic nadolol treatment reduces asthmatic airway hyper-responsiveness.

Enrollment: 10 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pre-bronchodilator FEV1 80% or greater than the predicted value.
• PC20 FEV1 ≤4 mg/ml on methacholine challenge test.
• Blood Pressure ≥ 100/65mm Hg.
• Pulse rate ≥ 60 beats/min.
• No significant health issues.
• Non-smoker or X-smoker < 10 pack/year.

Exclusion criteria

• History of upper/lower respiratory tract infection or asthma exacerbation within 6 weeks of first baseline visit.
• Currently diagnosed with chronic obstructive pulmonary disease (COPD).
• Used any oral or inhaled corticosteroids within 4 weeks of the first baseline visit.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Open Label treatment with oral Nadolol

Experimental group

Description:

Dose escalation through 1.25mgs, 2.5mgs, 5.0mgs, 10mgs, 20mgs, and 40mgs of nadolol at 2 week intervals as tolerated.

Treatment:

Drug: nadolol